✦ LIBER ✦

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

✍ Scribed by Kubitza, Dagmar; Roth, Angelika; Becka, Michael; Alatrach, Abir; Halabi, Atef; Hinrichsen, Holger; Mueck, Wolfgang

Book ID: 118251870
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 435 KB
Volume: 76
Category: Article
ISSN: 0306-5251
DOI: 10.1111/bcp.12054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Population Pharmacokinetics and Pharmaco

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

✍ Dr Wolfgang Mueck, Bengt I. Eriksson, Kenneth A. Bauer, Lars Borris, Ola E. Dahl 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 693 KB

Safety, Tolerability, Pharmacodynamics,

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin

✍ Kubitza, Dagmar; Becka, Michael; Mueck, Wolfgang; Zuehlsdorf, Michael 📂 Article 📅 2006 🏛 Sage Publications 🌐 English ⚖ 139 KB

The discovery and development of rivarox

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

✍ Perzborn, Elisabeth; Roehrig, Susanne; Straub, Alexander; Kubitza, Dagmar; Misse 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 588 KB

Management consensus guidance for the us

Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor

✍ Turpie, A. G. G.; Kreutz, R.; Llau, J.; Norrving, B.; Haas, S. 📂 Article 📅 2012 🏛 Schattauer 🌐 English ⚖ 382 KB

Effects of the oral, direct factor Xa in

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

✍ A. HILLARP; F. BAGHAEI; I. FAGERBERG BLIXTER; K. M. GUSTAFSSON; L. STIGENDAL; M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB

No Influence of Mild-To-Moderate Hepatic

No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

✍ Dr Karin Wåhlander, Maria Eriksson-Lepkowska, Lars Frison… 📂 Article 📅 2003 🏛 Springer International Publishing AG 🌐 English ⚖ 131 KB